Products Ocrelizumab
Ocrelizumab Phase 3 Completed ⚡ Active Interest: 40/100
Multiple Sclerosis, Primary Progressive
Multiple Sclerosis, Primary Progressive
Mar 2, 2011 → Dec 31, 2022
About Ocrelizumab Ocrelizumab is a phase 3 stage product being developed by Roche for Multiple Sclerosis, Primary Progressive. The current trial status is completed. This product is registered under clinical trial identifier NCT01194570. Target conditions include Multiple Sclerosis, Primary Progressive.
What happened to similar drugs? 20 of 20 similar drugs in Multiple Sclerosis, Primary Progressive were approved
Clinical Trials (16) NCT ID Phase Status Start Completion Indication NCT07483450 Approved Recruiting Jul 4, 2025 Apr 23, 2027 Relapsing Multiple Sclerosis NCT06675955 Phase 3 Recruiting Dec 13, 2024 Dec 31, 2029 Multiple Sclerosis NCT06780150 Pre-clinical Recruiting Sep 26, 2024 Mar 31, 2028 Multiple Sclerosis NCT05208840 Approved Withdrawn Sep 15, 2023 Jan 31, 2026 Multiple Sclerosis NCT05269004 Phase 3 Active May 3, 2022 Dec 31, 2027 Multiple Sclerosis NCT04998812 Approved Completed Apr 13, 2022 Jul 14, 2025 Multiple Sclerosis NCT04998851 Approved Completed Sep 16, 2021 Jan 13, 2025 Multiple Sclerosis NCT04075266 Phase 2 Active Jan 9, 2020 Dec 1, 2029 Multiple Sclerosis NCT03593590 Pre-clinical Completed Nov 12, 2018 Jan 19, 2026 Multiple Sclerosis NCT03691077 Phase 3 UNKNOWN Nov 11, 2018 Sep 1, 2024 Multiple Sclerosis NCT03599245 Phase 3 Completed Jul 12, 2018 Jul 17, 2025 Multiple Sclerosis NCT03523858 Phase 3 Active May 28, 2018 Nov 12, 2026 Progressive Multiple Sclerosis (PMS) NCT03085810 Phase 3 Terminated Mar 24, 2017 Apr 27, 2023 Multiple Sclerosis, Relapsing-Remitting NCT02861014 Phase 3 Completed Sep 9, 2016 Dec 15, 2020 Multiple Sclerosis, Relapsing-Remitting NCT01194570 Phase 3 Completed Mar 2, 2011 Dec 31, 2022 Multiple Sclerosis, Primary Progressive NCT02723071 Phase 1/2 Completed May 1, 2005 Jan 1, 2008 Non-Hodgkin's Lymphoma
Competing Products 20 competing products in Multiple Sclerosis, Primary Progressive
See all competitors Product Company Stage Hype Score mRNA-1195 Moderna Phase 2 NEX-20A Nanexa AB Phase 1 mRNA-2736 Moderna Phase 1 mRNA-2808 Moderna Phase 2 Placebo + Pirtobrutinib Eli Lilly Phase 2 Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide Eli Lilly Phase 1/2 agenT-797 MiNK Therapeutics Phase 1 Duloxetine Hydrochloride (HCI) + Placebo Eli Lilly Phase 3 Temferon Genenta Science Phase 1/2 CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) Celltrion Phase 3 CT-P53 + US-Ocrevus + EU-Ocrevus Celltrion Phase 3 CS-0777 tablets + CS-0777 tablets + CS-0777 tablets Daiichi Sankyo Phase 1 ASP7487, Velcade, Dexamethasone Astellas Pharma Phase 1/2 PHE885 Novartis Phase 2 Mirabegron + Placebo Astellas Pharma Approved Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + Placebo Astellas Pharma Approved Denileukin Diftitox (Ontak) Eisai Phase 1 Palonosetron Eisai Phase 2 BIW-8962 Kyowa Kirin Phase 1 KRN125(pegfilgrastim), PLR001(plerixafor) + KRN8601(filgrastim), PLR001(plerixafor) Kyowa Kirin Phase 2